JP2014509313A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509313A5
JP2014509313A5 JP2013552124A JP2013552124A JP2014509313A5 JP 2014509313 A5 JP2014509313 A5 JP 2014509313A5 JP 2013552124 A JP2013552124 A JP 2013552124A JP 2013552124 A JP2013552124 A JP 2013552124A JP 2014509313 A5 JP2014509313 A5 JP 2014509313A5
Authority
JP
Japan
Prior art keywords
nasal
nose
powder
ingested
sucking
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013552124A
Other languages
English (en)
Japanese (ja)
Other versions
JP5891249B2 (ja
JP2014509313A (ja
Filing date
Publication date
Priority claimed from DE102011009961A external-priority patent/DE102011009961A1/de
Application filed filed Critical
Publication of JP2014509313A publication Critical patent/JP2014509313A/ja
Publication of JP2014509313A5 publication Critical patent/JP2014509313A5/ja
Application granted granted Critical
Publication of JP5891249B2 publication Critical patent/JP5891249B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013552124A 2011-02-01 2012-01-09 7−アザインドール誘導体 Expired - Fee Related JP5891249B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011009961.1 2011-02-01
DE102011009961A DE102011009961A1 (de) 2011-02-01 2011-02-01 7-Azaindolderivate
PCT/EP2012/000067 WO2012104007A2 (de) 2011-02-01 2012-01-09 7-azaindolderivate

Publications (3)

Publication Number Publication Date
JP2014509313A JP2014509313A (ja) 2014-04-17
JP2014509313A5 true JP2014509313A5 (OSRAM) 2016-01-21
JP5891249B2 JP5891249B2 (ja) 2016-03-22

Family

ID=45554609

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013552124A Expired - Fee Related JP5891249B2 (ja) 2011-02-01 2012-01-09 7−アザインドール誘導体

Country Status (18)

Country Link
US (3) US8981101B2 (OSRAM)
EP (3) EP2746281B1 (OSRAM)
JP (1) JP5891249B2 (OSRAM)
KR (1) KR20140014158A (OSRAM)
CN (3) CN105712991B (OSRAM)
AR (1) AR085110A1 (OSRAM)
AU (1) AU2012213775B2 (OSRAM)
BR (1) BR112013019028A2 (OSRAM)
CA (2) CA3082435A1 (OSRAM)
DE (1) DE102011009961A1 (OSRAM)
EA (1) EA201300873A1 (OSRAM)
ES (3) ES2608317T3 (OSRAM)
HK (1) HK1226394A1 (OSRAM)
IL (1) IL227689A0 (OSRAM)
MX (1) MX2013008212A (OSRAM)
SG (1) SG192133A1 (OSRAM)
WO (1) WO2012104007A2 (OSRAM)
ZA (1) ZA201306542B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20130376A1 (es) * 2010-06-28 2013-03-30 Merck Patent Gmbh [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer
DE102010053347A1 (de) * 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
EP2817313B1 (en) * 2012-02-21 2016-09-07 Merck Patent GmbH Furopyridine derivatives
DE102012019369A1 (de) 2012-10-02 2014-04-03 Merck Patent Gmbh 7-Azaindolderivat
FR3001219A1 (fr) * 2013-01-22 2014-07-25 Centre Nat Rech Scient Inhibiteurs de kinases
GB201303109D0 (en) 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
RU2680100C9 (ru) 2013-03-15 2019-04-18 Плексксикон Инк. Гетероциклические соединения и их применения
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
CN106715419A (zh) 2014-09-26 2017-05-24 吉利德科学公司 用作tank‑结合激酶抑制剂化合物的氨基三嗪衍生物
EP3265072A1 (en) * 2015-03-04 2018-01-10 Dana-Farber Cancer Institute, Inc. Salicylate inhibitors of melk and methods of use
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
RU2018102685A (ru) * 2015-06-29 2019-08-02 Мерк Патент Гмбх СОЕДИНЕНИЯ-ИНГИБИТОРЫ TBK/IKKε И ИХ ПРИМЕНЕНИЕ
AU2016370916A1 (en) 2015-12-17 2018-06-07 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
WO2017102091A1 (en) 2015-12-18 2017-06-22 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
CN105906608B (zh) * 2016-05-03 2018-10-19 中山大学 8-氨基喹啉-松果体素杂联体及其药物组合物
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
GB201702947D0 (en) 2017-02-23 2017-04-12 Domainex Ltd Novel compounds
JP7131837B2 (ja) * 2017-06-19 2022-09-06 アビスコ セラピューティクス カンパニー リミテッド Csf-1r阻害活性を有するアザアリール誘導体、その製造方法および応用
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
ES3028093T3 (en) 2018-06-07 2025-06-18 Disarm Therapeutics Inc Inhibitors of sarm1
KR20200046680A (ko) * 2018-10-25 2020-05-07 한국과학기술원 Pdk1 저해제를 포함하는 역노화 유도용 조성물
WO2025016273A1 (zh) * 2023-07-14 2025-01-23 拜西欧斯(北京)生物技术有限公司 异喹啉衍生物、包含其的药物组合物以及它们的用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
JP2003500397A (ja) 1999-05-19 2003-01-07 スミスクライン ビーチャム パブリック リミテッド カンパニー Mrs阻害剤としての2−nh−ピリドンおよびピリミドン
JP5095216B2 (ja) 2003-11-14 2012-12-12 ローラス セラピューティクス インコーポレーテッド アリールイミダゾールおよびその抗癌剤としての使用
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
WO2005095400A1 (en) 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
UA87494C2 (en) * 2004-03-30 2009-07-27 Вертекс Фармасьютикалс Инкорпорейтед Azaindoles useful as inhibitors of jak and other protein kinases
FR2868422B1 (fr) * 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US20080153869A1 (en) * 2004-06-14 2008-06-26 Bressi Jerome C Kinase Inhibitors
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
US7511056B2 (en) 2004-11-10 2009-03-31 Eli Lilly And Company TGF-β inhibitors
EP1828180A4 (en) 2004-12-08 2010-09-15 Glaxosmithkline Llc 1H-pyrrolo [2,3-BETA] PYRIDINE
AU2006232620A1 (en) 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as CHK1, PDK1 and PAK inhibitors
US7541367B2 (en) 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
JP2007099640A (ja) * 2005-09-30 2007-04-19 Tsumura & Co 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
CN101374839A (zh) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
NZ601687A (en) * 2006-01-17 2014-03-28 Vertex Pharma Azaindoles useful as inhibitors of janus kinases
DE102006012617A1 (de) 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
CA2659582A1 (en) 2006-06-22 2007-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
JP5642963B2 (ja) 2006-06-30 2014-12-17 スネシス ファーマシューティカルズ,インコーポレイティド ピリジノニルpdk1阻害剤
JP2010514693A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー Pdk1阻害のためのキナゾリン
CA2679694A1 (en) 2007-03-13 2008-09-18 Merck & Co., Inc. Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1
US8367706B2 (en) 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
DE102007028515A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
WO2009054941A1 (en) 2007-10-25 2009-04-30 Merck & Co., Inc. Therapeutic compounds
CN101939324B (zh) 2008-02-25 2014-10-15 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
DE102008025751A1 (de) * 2008-05-29 2009-12-03 Merck Patent Gmbh 4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
CN101723936B (zh) * 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
DE102009019962A1 (de) 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
NZ603644A (en) * 2010-05-24 2014-10-31 Univ Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
PE20130376A1 (es) * 2010-06-28 2013-03-30 Merck Patent Gmbh [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer
DE102010053347A1 (de) 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate

Similar Documents

Publication Publication Date Title
JP2014509313A5 (OSRAM)
JP2013534227A5 (OSRAM)
JP2014526447A5 (OSRAM)
JP2013544781A5 (OSRAM)
JP2013541565A5 (OSRAM)
JP2015505541A5 (OSRAM)
Doktorovova et al. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation
EA201590286A1 (ru) Аэрозольное ингаляционное устройство
JP2013538214A5 (OSRAM)
RU2015121091A (ru) Порошки для ингаляции с ультранизкой плотностью
MX371521B (es) Sistema de inhalacion de polvo seco.
EA201591729A1 (ru) Пригодные для вдыхания агломераты частиц пористого носителя и тонкоизмельченного лекарственного средства
BR122021002471B8 (pt) Dispositivo de distribuição de droga nasal
WO2014012069A3 (en) Dry powder drug delivery systems and methods
MY191380A (en) Stabilized fixed dose drug composition having mometasone and olopatadine
ATE527976T1 (de) Vorrichtung zur lagerung, unmittelbaren zubereitung und verabreichung eines wirkstoffes
MY196072A (en) Liquid Inhalation Formulation Comprising RPL554
EA201591869A1 (ru) Композиция, содержащая для повышения стабильности лекарственной формы по меньшей мере два сухих порошка, получаемых распылительной сушкой
JP2014528470A5 (OSRAM)
JP2020527377A5 (OSRAM)
EA201700182A1 (ru) Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой
MX2016007181A (es) Medicamentos inhalables.
EP4233874A3 (en) Acetylsalicylic acid for reducing the risk of a thromboembolic event
MD20160061A2 (ro) Sistem de livrare a medicamentului compus din particule multiple
CA2991760C (en) DRY INHALATION POWDER FORMULATIONS